Herbert I Hurwitz Selected Research

Bevacizumab (Avastin)

4/2022	Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer.
1/2022	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
1/2022	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).
1/2022	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
6/2020	Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
1/2020	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
1/2019	An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
1/2019	Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
12/2018	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.
10/2018	Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Herbert I Hurwitz Research Topics

Disease

67	Neoplasms (Cancer) 04/2022 - 06/2003
51	Colorectal Neoplasms (Colorectal Cancer) 04/2022 - 01/2003
9	Disease Progression 01/2022 - 01/2003
8	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2003
8	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 01/2002
8	Adenocarcinoma 05/2014 - 01/2002
6	Diarrhea 10/2014 - 08/2005
5	Wounds and Injuries (Trauma) 08/2015 - 02/2003
5	Hypertension (High Blood Pressure) 06/2013 - 05/2005
5	Carcinoma (Carcinomatosis) 03/2008 - 07/2005
4	Neutropenia 01/2019 - 06/2013
4	Fatigue 01/2018 - 12/2009
4	Nausea 01/2018 - 06/2009
4	Anemia 12/2015 - 09/2012
4	Exanthema (Rash) 06/2013 - 08/2005
4	Rectal Neoplasms (Rectal Cancer) 06/2007 - 03/2004
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 08/2014
3	Ovarian Neoplasms (Ovarian Cancer) 06/2020 - 04/2010
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2020 - 01/2013
3	Thrombocytopenia (Thrombopenia) 01/2017 - 07/2012
3	Vomiting 10/2014 - 12/2009
3	Colonic Neoplasms (Colon Cancer) 03/2013 - 06/2003
3	Hemorrhage 01/2013 - 05/2005
3	Esophageal Neoplasms (Esophageal Cancer) 03/2008 - 03/2007
2	Breast Neoplasms (Breast Cancer) 06/2020 - 08/2005
2	Ovarian Epithelial Carcinoma 01/2020 - 11/2014
2	Esophagitis 01/2017 - 03/2007
2	Inflammation (Inflammations) 01/2017 - 12/2015
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2015 - 06/2012
2	Mucositis 07/2012 - 02/2011
2	Cholangiocarcinoma 11/2011 - 01/2009
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2008 - 03/2007
2	Pathologic Complete Response 03/2008 - 03/2007
1	Hepatocellular Carcinoma (Hepatoma) 06/2020
1	Glioblastoma (Glioblastoma Multiforme) 06/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/2020
1	Kidney Neoplasms (Kidney Cancer) 01/2020
1	Constipation 01/2018
1	Sarcoma (Soft Tissue Sarcoma) 01/2018

Drug/Important Bio-Agent (IBA)

54	Bevacizumab (Avastin)FDA Link 04/2022 - 01/2003
22	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2003
17	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2005
16	Fluorouracil (Carac)FDA LinkGeneric 01/2019 - 01/2003
15	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 01/2004
14	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 01/2004
13	Capecitabine (Xeloda)FDA Link 01/2022 - 02/2006
10	Monoclonal AntibodiesIBA 10/2019 - 01/2003
10	Leucovorin (Folinic Acid)FDA Link 01/2019 - 01/2003
8	Everolimus FDA Link 01/2018 - 01/2011
7	Cetuximab (Erbitux)FDA Link 01/2022 - 08/2006
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 03/2005
6	Gemcitabine FDA Link 01/2019 - 12/2009
6	Pharmaceutical PreparationsIBA 08/2015 - 08/2005
5	Messenger RNA (mRNA)IBA 03/2015 - 01/2002
4	LigandsIBA 01/2022 - 12/2005
4	Panitumumab (Vectibix)FDA Link 01/2021 - 01/2011
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 03/2007
4	Proteins (Proteins, Gene)FDA Link 11/2018 - 06/2014
4	EndoglinIBA 10/2018 - 09/2012
4	Angiogenesis InhibitorsIBA 11/2014 - 07/2003
3	SteamIBA 04/2022 - 01/2019
3	Carboplatin (JM8)FDA LinkGeneric 01/2020 - 03/2007
3	Lapatinib (GW572016)FDA Link 01/2019 - 08/2005
3	carotuximabIBA 10/2018 - 09/2012
3	pazopanib FDA Link 01/2017 - 06/2009
3	Imatinib Mesylate (Gleevec)FDA Link 01/2015 - 04/2010
3	Sunitinib (Sutent)FDA Link 01/2015 - 10/2007
2	Circulating Tumor DNAIBA 04/2022 - 01/2020
2	afliberceptIBA 11/2019 - 01/2013
2	Activin Receptors (Activin Receptor)IBA 10/2019 - 01/2014
2	Biological ProductsIBA 01/2019 - 12/2005
2	ProdrugsIBA 01/2017 - 06/2012
2	Phosphotransferases (Kinase)IBA 05/2015 - 08/2005
2	ParaffinIBA 03/2015 - 01/2011
2	intetumumabIBA 02/2015 - 03/2013
2	EnzymesIBA 10/2014 - 06/2013
2	Dasatinib (BMS 354825)FDA Link 04/2014 - 03/2013
2	Dihydrotachysterol (AT 10)IBA 07/2012 - 09/2011
2	lonafarnib (SCH 66336)IBA 11/2011 - 02/2011
2	eniluracilIBA 02/2006 - 03/2004
2	Carcinoembryonic AntigenIBA 06/2003 - 01/2002
1	atezolizumabIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	cabozantinibIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 11/2019
1	ascrinvacumabIBA 10/2019
1	regorafenibIBA 10/2019
1	Cytochrome P-450 CYP3A InhibitorsIBA 01/2019
1	Angiogenic ProteinsIBA 11/2018
1	Vascular Endothelial Growth Factor CIBA 11/2018
1	ontuxizumabIBA 01/2018

Therapy/Procedure

35	Therapeutics 01/2022 - 01/2002
32	Drug Therapy (Chemotherapy) 01/2022 - 01/2003
10	Radiotherapy 11/2011 - 03/2004
6	Chemoradiotherapy 11/2011 - 01/2002
2	Immunotherapy 06/2020 - 01/2002
2	Pancreaticoduodenectomy 05/2014 - 01/2002
2	Esophagectomy 03/2008 - 03/2007
2	Neoadjuvant Therapy 11/2007 - 01/2002